A recent study published in the Medicine (Baltimore) journal on type 2 diabetic patients (T2D), demonstrated that Dorzagliatin (Dual-Acting Glucokinase Activator) had positive outcomes in managing hypoglycemia by considerably lowering the HbA1c, fasting blood glucose (FBG), and postprandial glucose levels. It also promoted insulin secretion during the initial phase, maintaining steady hypoglycemic effects.

Yuqian Wu and researchers assessed the safety and efficacy of Dorzagliatin therapy for T2DM. A systematic search was performed across 7 databases from 2016 to August 2023 to identify relevant studies. Only randomized controlled trials (RCTs) comparing dorzagliatin with a placebo for treating T2DM were included. Data pertinent to the study were extracted, and the RevMan 5.4 software was used to conduct the meta-analysis.

Three RCTs involving a total of 1332 patients were considered in this analysis. Glycated haemoglobin (HbA1c) levels were used as the primary indicator of efficacy, with fasting blood glucose (FBG), 2-hour postprandial blood glucose, Homa-β, and Homa-IR serving as secondary outcome measures. The blood glucose levels decreased considerably along with improved insulin resistance in the Dorzagliatin group compared to the placebo. Importantly, no serious adverse events were reported. However, lipid-related indicators, particularly triglyceride levels, and the occurrence of hypoglycemia were higher in the dorzagliatin group compared to the placebo group, although the increase from baseline was modest.

There is a need for additional clinical studies given the incidence of adverse events, for example, raised blood lipids and possible cardiovascular risks, the study researchers concluded.